Table of Contents Author Guidelines Submit a Manuscript
Journal of Toxicology
Volume 2012, Article ID 308594, 7 pages
http://dx.doi.org/10.1155/2012/308594
Research Article

Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies

1Biologics Research, Janssen Research and Development, LLC, 145 King of Prussia Road, Radnor, PA 19087, USA
2Safety Assessment, AstraZeneca Pharmaceuticals, Pepparedsleden 1, 431 83 Mölndal, Sweden
3Haskell Global Centers for Health and Environmental Sciences, DuPont Central Research and Development, Newark, DE 19711, USA
4Safety Assessment, AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, MA 02451, USA

Received 15 March 2012; Accepted 10 April 2012

Academic Editor: J. J. Stegeman

Copyright © 2012 Linda R. Barone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Linda R. Barone, Scott Boyer, James R. Damewood Jr., James Fikes, and Paul J. Ciaccio, “Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies,” Journal of Toxicology, vol. 2012, Article ID 308594, 7 pages, 2012. https://doi.org/10.1155/2012/308594.